Barrier system and study objective
Identify the relevant interface—intestinal epithelium, blood–brain barrier or another tissue system—and whether the priority is transport, retention, injury or repair.
R&D service
Drug delivery & barrier permeability
Assess barrier integrity, injury and repair, then develop permeability or candidate-transport assays for the relevant tissue system.
View imageIntestinal barrier evidence
Answer barrier questions with permeability and tight-junction readouts
Mouse intestinal organoid studies combine FITC-Dextran permeability with F-actin/ZO-1 epithelial-junction readouts. Human IBD and BBB studies adapt the cell system, identity markers, tight-junction imaging and permeability assays to the available sample and study objective.
Study focus
What this study can help you decide
- 01How well does the candidate cross the relevant tissue barrier?
- 02How does treatment alter barrier structure and function?
- 03How do imaging and functional endpoints explain delivery performance together?
Study workflow
From barrier integrity to candidate transport and effects
Confirmed barrier identity, baseline function and assay performance give permeability results a clear biological context. The study brings together tissue-barrier context, delivery format, transport readouts and potential barrier injury.
Model identity and baseline function
Confirm cell identity, architecture, tight junctions and baseline permeability against predefined acceptance criteria before candidate testing.
Candidate exposure and permeability
Set donor/receiver orientation, time, concentration and controls around modality, formulation and exposure route, using FITC-Dextran, tracing, imaging or project-appropriate quantification.
Transport and barrier status
Analyze permeability with viability, morphology, F-actin, ZO-1 and other junction readouts to build an integrated view of candidate transport and barrier status.
Study images and readouts
Read barrier function through permeability and junction structure
FITC-Dextran, F-actin and ZO-1 results connect permeability change with epithelial structure for candidate and formulation studies.
View imageCytoskeleton and tight junctions: F-actin and ZO-1 immunofluorescence provides epithelial-structure and junction-status readouts.
TRiCBIO mouse intestinal organoid studyView the IBD model and barrier studyExpected study outputs
What you receive
Barrier baseline and batch QC
Model identity, tight-junction and baseline permeability results, with batch QC criteria.
Transport and barrier-effect results
Candidate transport or retention data alongside changes in viability, structure and barrier integrity.
Study report and next steps
Methods, raw data, study conditions and recommended next experiments, including recovery or mass-balance results where applicable.
Relevant model systems
Recommended model systems
TRiCBIO intestinal organoid studies combine morphology, permeability, viability and F-actin/ZO-1 readouts, with human programs designed around the sample and candidate. Blood–brain barrier studies extend this approach through endothelial–astrocyte systems, tight-junction imaging, and readouts of permeability and candidate effects.
PROJECT DISCUSSION
Match a barrier model to the delivery question
The candidate or formulation, target barrier, exposure conditions and permeability question shape the model, controls and assay panel.